AllSight
Companies · COR · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Cencora, Inc. (COR)

Cencora, Inc. (COR) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Cencora, Inc. (COR) stock — financials & valuation

Key numbers for Cencora, Inc. (COR): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 52/100 — a percentile rank of Cencora, Inc.’s fundamentals against Wholesale peers, weakest on financial health. A quality ranking, not a price prediction.

Market cap$59.1B
P / E22.5×
P / S0.2×
EV / EBITDA12.2×
Gross margin4.0%
Operating margin0.9%
Net margin0.8%
Return on equity86.0%
ROIC18.3%
Revenue growth5.1%
Debt / equity3.8×
Dividend yield0.8%

Is Cencora, Inc. overvalued? P/E looks fair vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks fair vs its 5-year range.

Independent of the events above — derived from Cencora, Inc.’s own financial statements and shown as context, never as advice.

Aug 14, 2026Director resignation
Cencora loses a director to fusion startup—no governance red flag disclosed
Aug 12, 2026No new info
Walgreens volume is leaving—but the market was warned last week
Aug 5, 2026
Earnings and revenue beat; outlook rises only modestly on buybacks.
Aug 5, 2026
Revolver expands to $7 billion; committed receivables capacity contracts.
Related companies in Wholesale-Drugs, Proprietaries & Druggists' Sundries
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact